[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Connecticut Children's Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":424},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,64,89,120,147,173,208,234,263,292,317,347,369,397],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100550390","echography-guided-surfactant-therapy-esther-for-preterm-infants-with-respiratory-failure-100550390",false,"NCT06446453","Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure","Inclusion Criteria:\n\n* The infant's parent\u002Flegal guardian can understand and willingly sign a written informed consent document for this study\n* Birth gestational age between 27w0d-36w6d\n* Diagnosis of respiratory failure secondary to RDS requiring respiratory support with non-invasive positive pressure ventilation\n\nExclusion Criteria:\n\n* Unable to obtain lung ultrasound between 1-2 hours of life\n* Infants already intubated or received surfactant before the point of care lung ultrasound\n* Infants born with congenital cardiac disease, congenital lung disease, or congenital facial\u002Fairway malformations\n* Infants born with chromosomal abnormalities\n* Infants with APGARs ≤ 5 at 10 minutes of life\n* Infants requiring cardiopulmonary resuscitation or therapeutic hypothermia in the first 6 hours of life","ALL","0 Hours","2 Hours",{"count":19,"type":20},52,"ESTIMATED","INTERVENTIONAL",[23],"NA","Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier surfactant therapy and may improve short-term respiratory outcomes. This study will test this theory by comparing lung ultrasound score-guided surfactant therapy for premature infants with RDS with our current surfactant administration guidelines.",[26,27,28],"Respiratory Distress Syndrome, Newborn","Pulmonary Surfactants","Intensive Care Units, Neonatal","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2024-06-25",{"date":37,"type":20},"2027-06",{"name":39,"class":40},"Connecticut Children's Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":41},"100366076","pain-and-weight-treatment-development-and-trial-of-paw-100366076","NCT04046562","Pain and Weight Treatment: Development and Trial of PAW","PAW","Inclusion Criteria:\n\n* Males and females between 12 and 18 years of age\n* Ability to speak, write and read English\n* A parent or guardian who speaks, writes and reads English\n* Signed consent and assent from the child and parent\n* Enrollment in a weight management program\n* Score greater than 3 on the Pain Burden Inventory at screening (in order to recruit adolescents who experience more than just general aches and pains).\n* Youth reporting musculoskeletal pain\n\nExclusion Criteria:\n\n* Parent or guardian unable to participate\n* Patients on weight reducing medications\n* Severe psychiatric illness (i.e., suicidal or hospitalization within past 6 months)\n* Medical conditions such as Type 1 diabetes","12 Years","18 Years",{"count":52,"type":20},50,[23],"Pediatric weight management efficacy is impacted by failure to complete treatment protocols and, for those that do complete treatment, a return to unhealthy behaviors. This project tests whether treating pain, a common comorbid condition to pediatric obesity, will enhance treatment. This study will generate results that can be translated into immediate improvements in care for families seeking treatment for pediatric obesity.",[56,57,58],"Obesity, Adolescent","Pain, Chronic","CBT",{"date":32,"type":33},{"date":61,"type":33},"2019-08-14",{"date":37,"type":20},{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":72,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":41},"100249773","trial-of-fetoscopic-endoluminal-tracheal-occlusion-feto-for-cdh-100249773","NCT02530073","Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH","Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)","FETO","Inclusion Criteria:\n\n* Pregnant women age 18 years and older, who are able to consent\n* Singleton pregnancy\n\nFetal\n\n* Normal Karyotype\n* Fetal Diagnosis of Isolated Left CDH with liver up\n* Gestation at enrollment prior to 29 wks plus 6 days\n* SEVERE pulmonary hypoplasia with Ultra Sound O\u002FE LHR \\\u003C 25%\n\nExclusion Criteria:\n\n* Pregnant women \\\u003C18 years of age.\n* Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy\n* Technical limitations precluding fetoscopic surgery\n* Rubber latex allergy\n* Preterm labor, cervix shortened (\\\u003C15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa\n* Psychosocial ineligibility, precluding consent\n* Diaphragmatic hernia: right-sided or bilateral, major associated anomalies, isolated left-sided with the O\u002FE LHR ≥ 25%\n* Inability to remain at FETO site during time period of tracheal occlusion, delivery and postnatal care","FEMALE",{"count":5,"type":20},[23],"The rationale for fetal therapy in severe congenital diaphragmatic hernia (CDH) is to restore adequate lung growth for neonatal survival.",[77],"Congenital Diaphragmatic Hernias",[79,70,80],"congenital diaphragmatic hernia","tracheal occlusion","2026-06-16",{"date":83,"type":33},"2026-06-18",{"date":85,"type":33},"2015-09",{"date":87,"type":20},"2030-08",{"name":39,"class":40},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100641376","improving-sexual-and-reproductive-health-communication-for-adolescent-and-young-adult-oncology-patients-100641376","NCT07658937","Improving Sexual and Reproductive Health Communication for Adolescent and Young Adult Oncology Patients","Improving Sexual and Reproductive Health Communication Between Adolescent and Young Adult Oncology Patients and Clinicians: ReSPECT Intervention Proof-of-Concept Testing","ReSPECT","Inclusion Criteria:\n\n* Age 15-25 years old\n* Has a cancer diagnosis\n* ≥2 months from diagnosis\u002Finitiation of therapy, whichever occurred later\n* Currently on cancer-directed therapy\n* Speaks and reads English\n* Approval from primary oncology team\n* Study participation by primary oncology clinician\n\nExclusion Criteria:\n\n* Not able to provide informed consent\u002Fassent\n* Insufficient cognitive functioning to complete study measures, as determined by a member of the patient's primary oncology team\n* Exceeds primary oncologist's participant limit (3 patients\u002Fclinician)","15 Years","25 Years",{"count":100,"type":20},30,[23],"The goal of this clinical trial is to learn if ReSPECT, which includes a pre-visit checklist for patients to complete and an informational website, can work well in practice to help adolescent and young adult oncology patients communicate with their clinicians about sexual and reproductive health (SRH). SRH includes topics such as how cancer may impact puberty and development, best methods for contraception during cancer treatment, fertility risk and fertility preservation strategies, and dating\u002Frelationships during and after cancer. The study will also help researchers better understand how to best measure the impact of ReSPECT on improving SRH communication for future testing of ReSPECT.\n\nThe main questions the study aims to answer are:\n\nHow well does ReSPECT work in practice? Do patients and clinicians like ReSPECT, and do they find it helpful? What are the best ways to test ReSPECT and measure whether it works?\n\nParticipants will:\n\nUse ReSPECT to support a conversation about SRH during an outpatient oncology clinic appointment Complete surveys before and after using ReSPECT Provide feedback on their experience using ReSPECT in a short interview",[104,105,106],"Health-Related Quality-of-Life","Cancer","Health Communication",[104,108,109,110,106,105],"Adolescent","Young Adult","Psychosocial Intervention","NOT_YET_RECRUITING","2026-06-15",{"date":114,"type":33},"2026-06-22",{"date":116,"type":20},"2026-11-15",{"date":118,"type":20},"2029-06-30",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":136,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":41},"100628280","accuracy-of-home-lactate-meter-and-accu-chek-glucometer-in-patients-with-glycogen-storage-disease-100628280","NCT07459582","Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease","Inclusion Criteria:\n\n1. Patients with diagnosed\u002Fconfirmed (by liver biopsy or genetic testing) Glycogen Storage Disease Type Ia\u002FIb (ICD 10 code: E74.01) or XI (74.09).\n2. For pediatric participants: Ability of child's parent\u002Flegal guardian to understand and the willingness to sign a written informed consent document\n3. For adolescents: assent to participate\n4. For adults: Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n1. Patients with Glycogen storage disease unspecified\n2. Patients not meeting inclusion criteria\n3. Patients unable to provide consent\n4. Patients who decline to be in the study","60 Years",{"count":128,"type":20},10,"OBSERVATIONAL","The goal of this study is to determine if the Lactate Plus meter is accurate compared to lab lactate levels, and to determine if the Accu chek guide glucometer is accurate compared to lab serum glucose levels in patients with Glycogen Storage Disease Types Ia, Ib and XI.\n\nTo determine this, patient's will have a one-time planned admission to Connecticut Children's for approximately 8 hours and receive hourly blood draws as well as finger-sticks.",[132,133,134,135],"Glycogen Storage Disease Type IA","Glycogen Storage Disease Type I","Glycogen Storage Disease Type IB","Glycogen Storage Disease Xi",[137,138],"lactate","blood glucose","2026-05-29",{"date":141,"type":33},"2026-06-01",{"date":143,"type":20},"2026-08",{"date":145,"type":20},"2027-12",{"name":39,"class":40},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":15,"minAge":155,"maxAge":49,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":41},"100509301","osa-18-in-children-with-mild-obstructive-sleep-apnea-can-it-be-a-helpful-decision-making-tool-100509301","NCT05911646","OSA-18 in Children With Mild Obstructive Sleep Apnea: Can it be a Helpful Decision Making Tool?","OSA-18","Inclusion Criteria:\n\n* Parent\u002Fcaregiver of child with an initial diagnosis mild obstructive sleep apnea defined as polysomnography AHI score between 1 and 5\n* Parent\u002Fcaregiver of child between 3 and 12 years of age\n* Parent\u002Fcaregiver of child who has been diagnosed with tonsillar hypertrophy grade 2 or higher\n\nExclusion Criteria:\n\n* Parent\u002Fcaregiver of child diagnosed with a syndromic or known neurologic condition and\u002For multiple (more than two) medical cardiac or respiratory medical conditions\n* Parent\u002Fcaregiver of child who has previously underwent tonsillectomy",true,"3 Years",{"count":157,"type":20},130,[23],"The concept is a novel research idea that incorporates the potential impact of patient quality of life (QOL) on decision-making for treatment of mild obstructive sleep apnea (OSA). Our hypothesis is that in children with mild OSA there is significant conflict with parental decision-making; in the absence of significant sleep apnea, there is limited research regarding comparative efficacy of various treatment options. The impact of a QOL questionnaire can be a significant deciding factor and may help guide management decisions in such situations.",[161,162],"Apnea, Obstructive Sleep","Obstructive Sleep Apnea",[164],"Mild Obstructive Sleep Apnea","2026-05-26",{"date":167,"type":33},"2026-05-28",{"date":169,"type":33},"2021-06-02",{"date":171,"type":20},"2027-05-31",{"name":39,"class":40},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":15,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100499276","phase-4-clinical-imaging-and-endoscopic-outcomes-of-children-newly-diagnosed-with-crohns-disease-100499276","NCT05781152","Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","CAMEO","Phase 1 Inclusion Criteria\n\n1. Age ≥ 6 years and \\\u003C 18 years at enrollment\n2. Suspected diagnosis of CD\n3. Stool culture if performed that is negative for routine enteric pathogens (Salmonella, Shigella, Campylobacter, E. coli 0157:H7) and Clostridium difficile toxin in patients presenting with diarrhea. If history of C. difficile then a minimum of 6 weeks duration from treatment start and negative repeat stool for C. difficile toxin.\n4. Parent\u002Fguardian consent and patient assent\n5. Ability to remain in follow-up for up to 6 months of initial observation followed by a minimum of 52 weeks after possible start of anti-TNF therapy\n\nPhase 1 Exclusion Criteria\n\n1. Diagnosis of CD following abdominal resectional surgery\u002Fappendectomy at initial presentation\n2. Investigator judgment that patient has high likelihood (\\>50%) of needing bowel resection within 3 months of diagnosis (i.e., presentation with perforation, bowel obstruction from stricture)\n3. Use of any oral CS for non-gastrointestinal indication within the four weeks prior to diagnostic assessment and biosampling (e.g., asthma)\n4. Use of any investigational drug within the past four weeks prior to diagnostic assessment and sampling\n5. Pregnancy\n6. Patients with poorly controlled medical conditions (e.g. diabetes, congestive heart failure)\n7. Previous treatment with immunomodulators within one year of enrollment or anti-TNF therapy within two years of enrollment for other medical conditions (e.g., juvenile idiopathic arthritis)\n8. Previous treatment with non-anti TNF biologics or small molecules for non-IBD indications in the past 6 months, with the exception of dupilumab (Dupixent) for asthma, eczema, or eosinophilic esophagitis\n9. Inability to have MRE because of claustrophobia or other reasons\n\nPhase 2 Inclusion Criteria\n\n1. Met all eligibility criteria for Phase 1 and participated in Phase 1\n2. Diagnosed with macroscopic CD involving the terminal ileum and\u002For colon by endoscopic evaluation and\u002For MRE\n3. MRE imaging within 6 weeks of ileocolonoscopy and no more than 4 weeks after starting initial therapy (TT). A limited 'research protocol' MRE is acceptable in participants who have undergone a clinical CTE during their initial diagnostic evaluation; see Manual of Procedures for details.\n4. Received at least one of the following as initial therapy upon diagnosis:\n\n   1. Corticosteroids\n   2. Immunomodulator\n   3. Aminosalicylic acids (5-ASA)\n   4. Defined nutritional therapy\n   5. Anti-TNF (adalimumab or infliximab)\n5. Commenced adalimumab or infliximab anti-TNF therapy guided by ROADMAB™ CDST as first therapy or within 180 days of diagnosis (TD), with or without concomitant immunomodulator\n\n6 a. Had ileal and rectal biopsies, OR b. Ileal biopsies are not obtained secondary to inflammatory or structural changes at the ileocecal valve or distal ileum that prevent ileal intubation. To be acceptable for Phase 2, the following additional criteria must be met: b1. Gross inflammation or obvious narrowing at the IC valve or distal ileum as documented by the video colonoscopy, AND b2. MRE documentation of TI inflammation with or without narrowing, OR c. Ileal biopsies are not obtained secondary to inflammatory or structural changes due to colonic CD.\n\n7\\. Parent\u002Fguardian consent and patient assent 8. Ability to remain in follow-up for a minimum of 52 weeks after start of anti-TNF therapy\n\nPhase 2 Exclusion Criteria\n\n1. Diagnosis of CD using video capsule endoscopy only with normal ileocolonoscopy and normal MRE\n2. Orofacial CD only\n3. Esophageal, gastric, duodenal, and\u002For jejunal CD only\n4. Severe complex fistulizing perianal disease +\u002F- abscess, or perianal disease requiring surgical intervention or likely to require on-going surgical intervention possibly including diversion. The placement of a seton is not exclusionary. Incision and drainage of a perirectal abscess is also not exclusionary.\n5. Perianal CD only with no evidence of luminal disease\n6. Internal fistulizing disease at diagnosis\n7. Initial IBD treatment with non-anti-TNF biologic or small molecule therapy\n8. Received any anti-TNF agent other than adalimumab or infliximab\n9. Investigator judgment that patient unlikely to return for clinical, endoscopic or MRE follow-up\n10. Inability to have MRE because of claustrophobia or other reasons\n11. Video of baseline endoscopy not available for central reading, unless otherwise approved by the Clinical Coordinating Center (Adequate photo documentation required)\n12. Underwent bowel resection within 3 months of diagnosis (TD)","6 Years","17 Years",{"count":183,"type":20},900,[185],"PHASE4","Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps\u002Fpain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.",[188],"Crohn Disease",[190,191,192,193,194,195,196,197,198],"crohn disease","children","pediatric","anti-TNF therapy","therapeutic drug monitoring","intestinal microbiome","inflammatory bowel disease","gene expression","genomic DNA","2026-05-22",{"date":201,"type":33},"2026-05-27",{"date":203,"type":33},"2023-06-10",{"date":205,"type":20},"2029-07-01",{"name":39,"class":40},26,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":154,"sex":15,"minAge":50,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":215,"briefSummary":216,"conditions":217,"keywords":223,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":41},"100634521","development-of-a-provider-focused-intervention-to-improve-health-outcomes-in-pediatric-sickle-cell-disease-100634521","NCT07540767","Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease","Inclusion Criteria:\n\n* Licensed health care provider (HCP) who provides care to youth with SCD\n* HCP employed by Connecticut Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia and primary work area is Hematology\u002FOncology\n\nExclusion Criteria:\n\n* HCP who does not provide care to youth with SCD\n* HCP is a medical trainee, not including fellows\n* HCP not employed by CT Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia\n* Not fluent in English",{"count":100,"type":20},[23],"The goal of this interventional study is to learn about the impact of an intervention for health care providers that teaches individuation and perspective-taking (IPT) skills to enhance patient-centered communication in pediatric sickle cell disease (SCD). The main question it aims to answer is:\n\nDoes an intervention that teaches individuation and perspective-taking (IPT) skills to pediatric sickle cell disease (SCD) health care providers (HCPs) enhance patient-centered communication?\n\nResearchers will compare the IPT intervention to a control group who will receive education about SCD pain management to see if the IPT intervention improves patient-centered communication.\n\nParticipants will complete baseline surveys and then be randomly assigned into the intervention or control group. After completing their assigned session (IPT training or education), they will be asked to complete the same surveys as completed at baseline.",[218,219,220,221,222],"Sickle Cell Disease","Sickle Cell Anemia in Children","Sickle Cell Disease (SCD)","Sickle Cell","Sickle Cell Anemia (HbSS)",[224,225],"sickle cell","pediatrics","2026-04-24",{"date":228,"type":33},"2026-04-29",{"date":230,"type":20},"2027-09-01",{"date":232,"type":20},"2030-06-30",{"name":39,"class":40},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":15,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":41},"100617937","interoceptive-awareness-and-function-in-adolescents-with-chronic-pain-100617937","NCT07325110","Interoceptive Awareness and Function in Adolescents With Chronic Pain","Study Group:\n\nInclusion Criteria:\n\n1. Adolescents seen as new patients in the pain clinic at Connecticut Children's\n2. Referred to occupational therapy services.\n3. Adolescents diagnosed with a form of chronic pain.\n4. Between the ages of 11 and 21 years at time of enrollment.\n5. If over 18, the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n6. If under 18, the parent\u002Flegal guardian, has the ability to understand and willingness to sign the informed consent document or the ability to use the short form process.\n7. Adolescents between the ages of 11 and less than 18 years with the ability to understand and willingness to sign assent.\n8. Adolescents who agree to therapeutic yoga as a planned part of their occupational therapy treatment plan.\n\nExclusion Criteria:\n\n1. Adolescents not receiving yoga as an element of their occupational therapy treatment plan.\n2. Adolescents with a cognitive impairment that would impede their ability to participate.\n3. Adolescents with a neuromuscular diagnosis, such as Cerebral Palsy, Spinal Muscular Atrophy, and Muscular Dystrophies, that are not appropriate for yoga as an element of their treatment plan for this study.\n4. Adolescents unwilling to complete surveys to participate in this research study.\n5. Adolescents who are currently actively practicing yoga\n6. Adolescents who are currently receiving occupational therapy at another location.","11 Years","21 Years",{"count":243,"type":20},49,"The main objectives of this study are to compare the levels of interoceptive awareness and self-reported function pre and post completion of an occupational therapy treatment plan. The target population are adolescents aged 11-21 years that are diagnosed with chronic pain and are seen through the Pain Team at Connecticut Children's. The primary aims are:\n\n* To compare the reported levels of interoceptive awareness in adolescents with chronic pain before and after their occupational therapy treatment plan.\n* To compare the reported levels of function in adolescents with chronic pain before and after their occupational therapy treatment plan.",[246,247,57],"Chronic Pain","Chronic Pain Syndrome",[249,250,251,252,253,254],"chronic pain","adolescents","interoceptive awareness","function","occupational therapy","yoga","2026-04-23",{"date":257,"type":33},"2026-04-27",{"date":259,"type":33},"2026-02-25",{"date":261,"type":20},"2028-12",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":15,"minAge":270,"maxAge":126,"enrollmentInfo":271,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":41},"100580901","accuracy-of-lactate-meter-in-gsdia-100580901","NCT06843330","Accuracy of Lactate Meter in GSDIa","Are Portable Lactate Monitoring Devices Accurate in Patients With Glycogen Storage Disease Ia When Compared to Blood Serum Lactates?","Inclusion Criteria:\n\n* Patients with diagnosed\u002Fconfirmed (by liver biopsy or genetic testing) Glycogen Storage Disease Type Ia (ICD 10 code: E74.01).\n* Connecticut Children's Emergency Department visit and\u002For admission to Connecticut Children's during time study is active\n* For pediatric participants: Ability of child's parent\u002Flegal guardian to understand and the willingness to sign a written informed consent document\n* For adults: Ability to understand and the willingness to sign a written informed consent\n\nExclusion Criteria:\n\n* Patients with Glycogen storage disease unspecified 74.00, or Ib\n* Patients not meeting inclusion criteria","0 Years",{"count":128,"type":20},"The goal of this observational study is to determine if home lactate meters (both capillary and serum sample) are accurate, compared to lab serum lactate in a population of patients with glycogen storage disease type 1a and to determine if the Accu Chek Guide glucometer (capillary sample) is accurate, in a population of patients with glycogen storage disease type 1a.",[274],"Glycogen Storage Disease Type Ia",[276,277,278,279,280,281,282,283],"Glycogen Storage Disease type Ia","Blood lactate","Glycogen Storage Disease Ia blood glucose","GSD I","GSDIa","Blood glucose","Accu chek glucometer","Lactate plus","2026-03-05",{"date":286,"type":33},"2026-03-06",{"date":288,"type":33},"2025-04-14",{"date":290,"type":20},"2027-12-10",{"name":39,"class":40},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":301,"conditions":302,"keywords":306,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":41},"100497237","the-impact-of-blood-flow-restriction-training-in-adolescents-after-acl-reconstruction-a-randomized-controlled-trial-100497237","NCT05754632","The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Prior to surgery participated in \\>50 hours\u002Fyear of level I or II sports as defined by Noyes et al and planned to return to prior level.\n\nLevel I Sports (4-7 days\u002Fweek) Jumping, hard pivoting, cutting (basketball, volleyball,football, soccer, gymnastics, skiing. wrestling)\n\n* Level II sports (1-3 days\u002Fweek) Jumping, hard pivoting, cutting (basketball, volleyball,football, soccer, gymnastics, skiing. wrestling)\n* Completion of postoperative rehabilitation following standard protocols\n* Orthopedic surgical intervention and physical therapy completed at Connecticut Children's.\n\nExclusion Criteria:\n\n* An additional lower extremity injury at time of knee injury or previous surgical intervention on the knee (ipsilateral and contralateral)\n* Multiple ligament ruptures or trauma\n* Weight bearing restrictions for greater than 4 weeks after surgery due to concomitant pathology such as meniscal root\u002Fradial repair, chondral pathology, or multi-ligament pathology\n* Follow-up surgical procedures including, but not limited to, post-operative arthrofibrosis Inability to attend regular physical therapy sessions (≥80% of patient treatment sessions and all assessment visits\n* Contraindications to performing BFRT including known history of central or peripheral neurologic impairments, cardiac or metabolic condition or history of deep vein thrombosis (DVT).",{"count":299,"type":20},40,[23],"While there are a number studies that have reported on the use of blood flow restriction training (BFRT) in the adult population, there is limited information about the use of BFRT in the adolescent population. This study aims to evaluate the use of BFRT in conjunction with traditional anterior ligament reconstruction (ACLR) rehabilitation in adolescents.\n\nThe purpose of this study is to compare the addition of a BFRT based exercise protocol to a standard ACL rehabilitation protocol in adolescents. Does the addition of BFRT-based exercise improve strength, hypertrophy, and patient reported outcomes after ACLR in the adolescent population?",[303,304,305],"Anterior Cruciate Ligament Injuries","Knee Injuries","Quadriceps Muscle Atrophy",[307,308],"physical therapy","rehabilitation","2026-01-05",{"date":311,"type":33},"2026-01-07",{"date":313,"type":33},"2023-06-08",{"date":315,"type":20},"2029-05-01",{"name":39,"class":40},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":154,"sex":15,"minAge":323,"maxAge":241,"enrollmentInfo":324,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":326,"conditions":327,"keywords":335,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":41},"100610171","assessment-and-educational-intervention-to-reduce-ultra-processed-food-consumption-in-pediatric-patients-with-ibd-100610171","NCT07224113","Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD","Inclusion Criteria:\n\n* Diagnosis of IBD (Crohn's disease, Ulcerative Colitis, IBD-U) for at least 3 months\n* Age 10 through \\\u003C 22 years at the time of enrollment (i.e., up to the day before the 22nd birthday)\n* Followed by a gastroenterologist at Connecticut Children's\n* IBD in clinical remission based on calculated PUCAI score \\\u003C10 or PCDAI score of \\\u003C10\n* Receiving medical infusions at CCMC Infusion Center as part of IBD treatment\n* Participants must be on full oral intake and not have major dietary restrictions or require oral nutrition supplements\n\nExclusion Criteria:\n\n* Following a medically prescribed or restrictive diet such as Crohn's Disease Exclusion Diet (CDED), ketogenic diet, Specific Carbohydrate Diet (SCD), low FODMAP diet, gluten-free diet, paleo, or Whole30.\n* Receiving any nutrition through feeding tubes (including nasogastric \\[NG\\], nasojejunal \\[NJ\\], gastrostomy \\[G\\], or gastrojejunostomy \\[GJ\\] tubes)\n* History of bowel surgery within 3 months of study start affecting ability to sustain normal enteral intake\n* Non-English-speaking participants (as translation and short-form consent processes will not be used for this study)","10 Years",{"count":325,"type":20},120,"This study explores whether simple nutrition education can help children and teens with inflammatory bowel disease (IBD) eat fewer ultra-processed foods (UPFs). UPFs include packaged snacks, sugary drinks, and fast food-items that are high in added sugars, fats, and artificial ingredients. Participants will complete online food recalls to measure what they eat and will then receive either nutrition handouts alone or handouts plus a short educational video about UPFs. Researchers will compare changes in UPF intake between the two groups after several weeks and ask families how useful and acceptable they found the materials. The goal is to identify an effective, practical way to support healthier eating habits and long-term gut health in pediatric IBD.",[328,329,330,331,332,333,334],"IBD","Crohn Disease (CD)","Ulcerative Colitis (UC)","Inflammatory Bowel Disease (IBD)","Ultra Processed Food","Nutrition Assessment","DGBI",[328,336,188,337,338],"Inflammatory Bowel Disease","Ulcerative Colitis","Ultra processed food","2025-11-17",{"date":341,"type":33},"2025-11-19",{"date":343,"type":33},"2025-11-10",{"date":345,"type":20},"2026-07-30",{"name":39,"class":40},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":15,"minAge":355,"maxAge":4,"enrollmentInfo":356,"targetDuration":155,"studyType":129,"phases":4,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":41},"100507563","utility-of-pcd-diagnostics-to-improve-clinical-care-100507563","NCT05889013","Utility of PCD Diagnostics to Improve Clinical Care","A Clinical Study to Gather Data on the Utility of Tests That Are Used to Make a Diagnosis of Primary Ciliary Dyskinesia (PCD)","PCD","Inclusion Criteria:\n\n* Age ≥ 2 years of age\n* Must have two of the following clinical history points:\n* Neonatal respiratory distress\n* Chronic nasal congestion\u002Frunny nose\n* Chronic cough\n* Situs\u002Flaterality defects\n* Bronchiectasis\n* Ability to provide informed consent or consent of parent\u002Fguardian and ass\n\nExclusion Criteria:\n\n* Recent history of sinus surgery or bloody nose in the past week\n* Age \\\u003C 2 years of age\n* Inability to tolerate probe in nose\n* Sinusitis or other respiratory exacerbation currently being treated with antibiotics\n* Admitted to hospital for respiratory exacerbation (inpatient status)\n* Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by the IRB)\n* Any other reason for which the study investigators feel the patient is not a good candidate to complete the testing","2 Years",{"count":52,"type":20},"This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).",[359],"Primary Ciliary Dyskinesia",[353,361],"nasal nitric oxide testing","2025-09-19",{"date":364,"type":33},"2025-09-22",{"date":366,"type":33},"2023-10-17",{"date":261,"type":20},{"name":39,"class":40},{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":15,"minAge":97,"maxAge":98,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":383,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":41},"100591564","improving-communication-between-aya-oncology-patients-and-clinicians-a-patient-centered-intervention-100591564","NCT06982066","Improving Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention","Improving Health-Related Quality of Life Communication Between AYA Oncology Patients and Clinicians: A Patient-Centered Intervention","Inclusion Criteria\n\nAdolescent and Young Adult Oncology Patients\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Be aged 15-25 years old at time of enrollment.\n2. Have a cancer diagnosis and currently be on cancer-directed therapy with at least one of the following:\n\n   1. Chemotherapy: any anticancer drug to treat the cancer diagnosis, including immunotherapy.\n   2. Radiotherapy: any radiotherapy to treat the cancer diagnosis.\n   3. Surgery: any surgery to remove cancer including partial of total resections. Biopsies are not considered surgery.\n3. Be greater than or equal to 2 months from diagnosis\u002Finitiation of therapy, whichever occurred later.\n4. Be able to speak and read English\n5. Have permission to participate from a member of the patient's primary oncology team.\n6. Provision to sign and date the consent\u002Fassent form.\n7. Active study participation of primary oncology clinician\n8. Patient must have primary oncology care at Connecticut Children's Center for Cancer \\& Blood Disorders of Children's Hospital Los Angeles Cancer \\& Blood Disease Institute\n\nExclusion Criteria\n\nAn individual who meets and of the following criteria will be excluded from participation in this study:\n\n1. Not currently on cancer-directed therapy.\n2. Unable to speak and read English.\n3. Insufficient cognitive functioning to complete study measures (as determined by a member of the patient's primary oncology team)\n\nPediatric Oncology Clinicians\n\n1\\. Be a pediatric oncology physician, clinical fellow, or advanced practice provider (including nurse practitioners and physician assistants) that provides clinical care for AYA patients with cancer",{"count":377,"type":20},60,[23],"The overarching goal is to develop and demonstrate proof-of-concept of ReSPECT (Reproductive and Sexual Health Patient Education and Communication Tool), a multi-modal communication intervention to improve adolescent and young adult (AYA)- clinician sexual and reproductive health (SRH) communication in the outpatient oncology clinic setting.",[381,382],"Pediatric Cancer","Adolescent and Young Adult Cancer",[384,385,386,387,388],"adolescent young adult","sexual health communication","cancer","patient provider communication","sexual and reproductive health","2025-08-11",{"date":391,"type":33},"2025-08-14",{"date":393,"type":33},"2025-02-10",{"date":395,"type":20},"2029-06-29",{"name":39,"class":40},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":154,"sex":15,"minAge":403,"maxAge":98,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":423},"100508259","phase-4-subpectoral-bupivacaine-for-pain-management-in-adolescent-reduction-mammaplasty-100508259","NCT05898087","Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty","Inclusion Criteria:\n\n1. Female\n2. Age 13-25 at the time of surgery\n3. Undergoing bilateral reduction mammaplasty at Connecticut Children's from 1\u002F1\u002F2022-12\u002F31\u002F2025.\n4. Ability of child's parent\u002Flegal guardian to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with history of substance use disorder or \"chronic pain\" defined as pain requiring management and treatment by a pain management specialist.\n2. Patients already taking narcotics at the time of surgery.\n3. Patients with a history of hepatic or renal dysfunction.\n4. Patients with known allergy to bupivacaine.\n5. Patients who are pregnant, determined by urine testing in pre-operative area.\n6. Patients who are non-verbal or have developmental delays that would result in inability to report reliable pain scores.\n7. Patients with significant post-operative complications\n8. Patients not meeting inclusion criteria.\n9. Patients lost to follow-up- they must be seen within 1 week and 4 weeks post-operatively","13 Years",{"count":405,"type":20},128,[185],"The main question this randomized control trial aims to answer is:\n\n• Is the use of intraoperative subpectoral bupivacaine associated with decreased post-operative pain in adolescent patients who undergo bilateral reduction mammaplasty\n\nParticipants will be randomized into the study group that intraoperatively receives 30cc of subpectoral bupivacaine injections or into the control group that intraoperatively receives 30cc of injectable saline subpectorally. All participants will keep a pain log and pain medication log at home for the first week following surgery.\n\nResearchers will compare to see if patients who receive subpectoral bupivacaine have lower pain scores in the PACU, and lower use of narcotics post-operatively when compared to the control group who receive injectable saline.",[409,410],"Macromastia","Post-operative Pain",[412,413,414],"macromastia","post-operative pain","bupivacaine","2025-05-23",{"date":417,"type":33},"2025-05-29",{"date":419,"type":33},"2022-04-01",{"date":421,"type":20},"2026-04-01",{"name":39,"class":40},2,""]